Amprenavir

Usual Dosing (Adults)

Production of amprenavir was discontinued by the manufacturer December 31, 2004; a prodrug version (fosamprenavir) is available.

LEXIVA (fosamprenavir calcium) : Therapy-Naive Adults: LEXIVA 1,400 mg twice daily; LEXIVA 1,400 mg once daily plus ritonavir 200 mg once daily; LEXIVA 1,400 mg once daily plus ritonavir 100 mg once daily; LEXIVA 700 mg twice daily plus ritonavir 100 mg twice daily. Protease Inhibitor-Experienced Adults: LEXIVA 700 mg twice daily plus ritonavir 100 mg twice daily. Pediatric Patients (2 to 18 years of age): Dosage should be calculated based on body weight (kg) and should not exceed adult dose. Hepatic Impairment: Recommended adjustments for patients with mild, moderate, or severe hepatic impairment.

Dosing Considerations

LEXIVA Tablets may be taken with or without food. LEXIVA Suspension: Adults should take without food; pediatric patients should take with food.

Renal Dosing

Renal Impairment
The impact of renal impairment on amprenavir elimination in adult patients has not been studied. The renal elimination of unchanged amprenavir represents approximately 1% of the administered dose; therefore, renal impairment is not expected to significantly impact the elimination of amprenavir.

Hemodialysis

Insufficient data

Reference(s)

National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.